CD274 and non-small cell lung carcinoma: In the largest real-world study conducted on 2368 advanced NSCLC patients, 22% had PD-L1 TPS ≥ 50%, 52% PD-L1 TPS ≥ 1%, and 48% PD-L1 TPS < 1%.